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Purpose: Bleeding is the major side effect of thrombolysis with alteplase (tissue plas-
minogen activator, t-PA) used for the treatment of acute ischemic stroke. Life-threatening
intracranial, retroperitoneal, gastrointestinal, respiratory, and genitourinary bleeding can
occur with the use of t-PA. Vitreo-retinal bleeding in the context of acute ischemic stroke
treatment has not been reported in the literature before and therefore is not posed as a
potential risk during decision making. Here we describe the ﬁrst reported case of vitreo-
retinal hemorrhage due to alteplase administration in a patient with acute ischemic stroke.
Summary: An 84-year-old white male presented to the emergency room with complaints
of right arm and leg weakness.The onset of symptoms was approximately 30min prior to
presentation to the emergency room. After ruling out contraindications including the pres-
ence of hemorrhage on head CT scan, patient was administered alteplase within 2hours
of symptom onset. Four hours after the administration of alteplase, the patient developed
right-sidedvisionchanges.ArepeatCTscandemonstratedanewlydevelopedrightintraoc-
ular hemorrhage.Throughout the hospital course, patient’s neurological status improved,
but he continued to have right-sided visual loss. Conclusion: Clinicians should be aware
of the potential for ocular hemorrhage especially in high-risk patients. The likelihood of a
subsequent vision-loss needs to be therefore discussed with the patient and family in such
situations.
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INTRODUCTION
Strokeisoneof theleadingcausesof deathinUnitedStates(Roger
et al., 2011). The use of intravenous tissue plasminogen activa-
tor (t-PA) in eligible patients with acute ischemic stroke has been
shown to improve neurological recovery and reduce the incidence
of disability (The National Institute of Neurological Disorders,
1995; Package Insert Alteplase, 2005). Prior to the administra-
tion of t-PA, the beneﬁts and risks of this therapy are explained
to the patients. Risks mainly include intracranial, retroperitoneal,
gastrointestinal, respiratory, and/or genitourinary bleeding. The
potential for intraocular hemorrhage and subsequent visual loss
is not part of the discussion mostly due to the rarity of this
situation and ignorance of the factors that may increase risk.
A review of literature using MEDLINE and EMBASE databases
utilizing the search terms “tissue plasminogen activator,” “acute
ischemicstroke,”“thrombolysis,”“ocular,”and“hemorrhage”failed
toretrieveanyreportsofocularbleedingduetot-PAinthecontext
of acute ischemic stroke treatment. On the other hand,in patients
with acute myocardial infarction (MI), ocular hemorrhage has
been reported as a very uncommon complication of thrombolytic
therapy (Mahaffey et al., 1997). Intraocular hemorrhage after
reteplase administration has been reported in a 66-year-old man
with a history of hypertensive retinopathy who presented with
acute MI (Kaba et al., 2005). This patient was eventually able to
perceive hand movements with the affected eye. Similarly, other
cases have been reported in patients with acute MI and majority
of them had a history of ophthalmic disease (Chorich et al.,1998;
Berry et al., 2002; Djalilian et al.,2003).
Intraocular hemorrhage and subsequent visual loss as a result
of treatmentforischemicstrokecanbeadevastatingcomplication
even if the patient otherwise has a signiﬁcant neurological recov-
ery. Here we describe the ﬁrst reported case of vitreo-retinal hem-
orrhageleadingtopermanentvisuallossaftert-PAadministration
in a patient with acute ischemic stroke.
CASE PRESENTATION
An 84-year-old white male presented to the emergency room with
complaints of right arm and leg weakness. The onset of symp-
toms was approximately 30minutes prior to presentation to the
emergency room. The patient had no dysarthria, aphasia, vision,
or hearing changes. There was no history of a recent fall, injury,
or seizures. Past medical history included hypertension, type 2
diabetesmellitus,hyperlipidemia,bilateralretinopathyfromlong-
standing diabetes and hypertension, bilateral cataracts, benign
prostatichypertrophy,andinvasiveadenocarcinoma.Pastsurgical
historyincludedlaminectomy(1yearprior)andcolonoscopywith
polypremoval(2daysprior).Theonlydrugallergythepatienthad
wastopenicillin.Priortoadmission,hismedicationswereaspirin,
metformin,metoprolol,multivitamin,andsimvastatin.Socialand
family histories were not pertinent to this case.
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FIGURE1|C Tscan image prior to t-PA.
FIGURE2|C Tscan image demonstrating ocular hemorrhage.
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In the emergency room, patient’s vital signs were stable with
an average blood pressure around 160/60mmHg. Patient’s phys-
ical examination revealed weakness and decreased sensation on
the right side. Of note, patient’s eye exam was normal with no
vision changes. An urgent CT scan of the head was performed
which was negative for any intracranial or ocular hemorrhage
(Figure 1).
Thedecisiontoadministert-PAwasmadesincethepatientmet
the inclusion criteria and had no contraindications (The National
InstituteofNeurologicalDisorders,1995;PackageInsertAlteplase,
2005). The risks and beneﬁts of therapy were well explained to
the patient and his family. The potential for intracranial hem-
orrhage and speciﬁcally gastrointestinal hemorrhage, in view of
patient’s recent colonoscopy, were also discussed in detail. Within
2hours after the onset of symptoms, patient was administered
alteplase, according to the standard weight-based dosing protocol
(Package Insert Alteplase, 2005). Patient was frequently evaluated
for any change in neurological status and his blood pressure was
appropriately maintained throughout this time period.
Four hours after the administration of alteplase, the patient
developed bright-red-blood-per-rectum and new onset black–red
visual loss in the right eye. Other than the visual changes, rest
of the physical and neurological exam remained unchanged. A
repeat CT scan demonstrated a new right intraocular hemorrhage
(Figure 2). There was no evolution of the infarct or evidence of
hemorrhage in the brain. Patient’s hemoglobin and vital signs
remained relatively stable during this time. Evaluation by oph-
thalmology and neurology consultants conﬁrmed the presence of
a right-sided vitreo-retinal hemorrhage. Follow-up MRI of the
brain conﬁrmed the presence of the intraocular bleeding along
with an acute/subacute left parietal infarct.
Throughout the hospital stay, patient continued to have right
ocular visual loss even though his neurological status improved.
Eventually, the patient underwent in-patient rehabilitation and
was subsequently discharged without any further complications.
At discharge, patient was almost back to his baseline in regards
to activities and functionality except for visual loss in the right
eye. Follow-up 8months later revealed that patient had no
vision in the right eye except for perception of light in the
periphery.
DISCUSSION
Previously reported intraocular hemorrhage due to t-PA was in
acute MI patients. The case we described here is the ﬁrst one to
report permanent visual loss as a complication of t-PA in patients
with acute ischemic stroke. Since the patient had no visual deﬁcits
orradiologicalevidenceofintraocularhemorrhagepriortoadmis-
sion,thiscomplicationcanbeattributedtotheuseof t-PA.Similar
topreviouslyreportedcases,ahistoryofretinopathyinourpatient
makes one wonder if patients with a history of ocular disease are
at higher risk for intraocular hemorrhage leading to visual loss.
This being a single case report in a patient with acute ischemic
stroke, more reports and/or studies are required to conﬁrm this
relationship.
Bleeding from any organ or site is a well-known risk of using
t-PA. Nonetheless,permanent loss of vision can be a very difﬁcult
situation for some patients, in spite of the potential neurological
recovery they might have. Even though salvaging the brain is of
greater importance, the possibility of this complication needs to
be discussed with high-risk patients to help make an informed
decision.
CONCLUSION
Clinicians should be aware of the risk of visual loss after t-PA
administration in high-risk patients. In patients with prior his-
tory of ocular disease, the risk of hemorrhage and subsequent
irreversible vision loss needs to be discussed with the patient and
family.
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